Avience Biomedicals Ltd Management Discussions

1. Industry Overview

The healthcare and in-vitro diagnostics industry continues to play a critical role in supporting timely disease detection, diagnosis and effective patient management. Increasing awareness regarding preventive healthcare, growing demand for early diagnosis, expansion of healthcare infrastructure and technological advancements in diagnostic solutions are contributing to the continued development of the diagnostics and medical devices sector.

The demand for reliable, accurate and cost-effective diagnostic products remains significant across hospitals, diagnostic laboratories, healthcare institutions and other medical facilities. The industry is also witnessing increasing adoption of automated diagnostic systems, point-of-care testing and improved laboratory technologies.

2. Business Overview

The Company is engaged in the business of manufacturing and supplying a range of diagnostic products and medical devices catering to diverse healthcare requirements. The Companys product portfolio includes essential diagnostic kits such as Viral Transport Media (VTM), COVID-19 diagnostic kits, HIV diagnostic kits, HBsAg kits, Malaria and Dengue diagnostic kits, along with various serology products.

The Company also offers Biochemistry Analysers and Biochemistry Reagents, thereby providing a broader range of diagnostic solutions for healthcare institutions and laboratories.

Through its diversified product portfolio, the Company seeks to address various diagnostic and healthcare needs while maintaining a focus on product quality, reliability and accessibility.

3. Business Performance

During the year under review, the Company continued to focus on strengthening its presence in the diagnostics and medical devices segment. The Companys diversified product portfolio enables it to cater to different segments of the healthcare industry and reduces dependence on any single category of diagnostic products.

The Company continues to focus on improving operational efficiency, strengthening its product portfolio and expanding its market reach. Management remains committed to developing and supplying diagnostic solutions that meet the evolving requirements of healthcare providers and end users.

4. Opportunities and Growth Prospects

The increasing emphasis on preventive healthcare, early disease detection and regular health screening p resents significant opportunities for the diagnostics industry. Growing healthcare expenditure, expansion of diagnostic laboratories and hospitals, increasing awareness o f infectious diseases and technological advancement in diagnostic equipment are expected to support demand for diagnostic products.

The Companys presence across multiple product categories, including infectious disease diagnostic kits, serology products, biochemistry analysers and reagents, provides opportunities to participate in different segments of the diagnostics market.

The Company intends to leverage these opportunities by strengthening its product portfolio, enhancing its distribution and market presence and focusing on quality and customer requirements.

5. Risks and Concerns

The Companys operations are subject to various risks associated with the healthcare and medical diagnostics industry. These include regulatory requirements, competition, changes in technology, product quality and performance requirements, availability and cost of raw materials, supply-chain disruptions and changes in market demand.

The diagnostics industry is also subject to stringent quality and regulatory standards. Any changes in applicable laws, regulations, certification requirements or approval processes may affect the Companys operations and costs.

The Company seeks to manage these risks through appropriate quality-control processes, compliance with applicable regulatory requirements, supplier management, product diversification and continuous monitoring of market and industry developments.

6. Internal Control Systems

The Company maintains appropriate internal control systems commensurate with the size and nature of its operations. The internal controls are designed to safeguard the Companys assets, ensure accuracy and reliability of financial reporting, promote operational efficiency and ensure compliance with applicable laws and regulations.

The management periodically reviews the adequacy and effectiveness of internal control systems and takes corrective measures wherever required.

7. Human Resources

Human resources continue to b e an important component of the Companys operations. The Company seeks to maintain a competent and committed workforce and encourages employees to contribute towards operational efficiency, quality and achievement of organisational objectives.

The Company continues to focus on employee development, workplace discipline and a positive working environment.

8. Outlook

The outlook for the diagnostics and medical devices sector remains encouraging, supported by increasing healthcare awareness, demand for early diagnosis, expansion of healthcare facilities and continued technological development.

The Company remains focused on strengthening its position in the diagnostic products and medical devices segment through product diversification, operational efficiency, quality assurance and expansion of its market reach.

Management believes that the Companys diversified portfolio comprising diagnostic kits, serology products, biochemistry analysers and biochemistry reagents provides a foundation for sustainable growth, subject to prevailing market, regulatory and economic conditions.

9. Cautionary Statement

Statements in this Management Discussion and Analysis describing the Companys objectives, expectations, estimates or predictions may constitute forward-looking statements within the meaning of applicable laws and regulations. Actual results could differ materially from those expressed or implied due to various factors, including changes in economic conditions, market d emand, competition, regulatory requirements, availability and cost of inputs, technological developments and other factors beyond the Companys control.

By order of the Board
For AVIENCE BIOMEDICALS LIMITED
( formerly known as Avience Biomedicals Private Limited )

Sd/-	Sd/-
DHARAM DEO CHOUDHARY	RAM NAGINA CHOUDHARY
Managing Director	Whole-Time Director
DIN: 02804625	DIN: 02804667
Flat-48, Suryodaya Apartment,	Flat No B-411, The Patel CGHS Ltd Plot
Pocket-8, Sec-17, Dwarka	No -4 , Sector 4, Dwarka South West Delhi,
Delhi- 110078, India	New Delhi-110075,India

Place: New Delhi
Date: 07.09.2026